NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 67.40.
Share Price | ₹13,695.2 | Jul 23,2025 |
Market Cap | ₹17,529.9 Cr | |
Earnings-TTM | ₹260.1 Cr | TTM-Consolidated Results |
Price/Earnings | 67.40x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹17,529.9 Cr] as on Jul 23,2025
(/) Earnings [ ₹260.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 67.40x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 67.40 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 30.88x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NEULAND LABORATORIES | 260.11 | 67.40 | 17,529.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,980.10 | 36.77 | 403,712.0 |
DIVIS LABORATORIES LTD | 2,191.00 | 80.61 | 176,623.0 |
CIPLA LTD | 5,291.05 | 22.49 | 119,010.0 |
TORRENT PHARMACEUTICALS LTD | 1,911.00 | 62.94 | 120,285.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 18.18 | 104,118.0 |
MANKIND PHARMA LTD | 2,003.22 | 53.59 | 107,349.0 |
ZYDUS LIFESCIENCES LTD | 4,614.80 | 20.98 | 96,824.9 |
LUPIN LTD | 3,306.26 | 26.53 | 87,716.0 |
AUROBINDO PHARMA LTD | 3,515.26 | 18.46 | 64,875.5 |
ABBOTT INDIA LTD | 1,414.44 | 52.20 | 73,831.8 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.18x |
Max industry PE | 80.61x |
Median industry PE | 36.77x |
Average industry PE | 41.83x |
You may also like the below Video Courses